Gilead Sciences, Inc. (GILD) Holdings Lowered by Fiera Capital Corp
Fiera Capital Corp cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 23.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,775 shares of the biopharmaceutical company’s stock after selling 14,105 shares during the period. Fiera Capital Corp’s holdings in Gilead Sciences were worth $3,310,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in GILD. Keel Point LLC boosted its holdings in shares of Gilead Sciences by 0.4% in the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 11 shares in the last quarter. West Oak Capital LLC boosted its holdings in shares of Gilead Sciences by 0.7% in the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 32 shares in the last quarter. First Heartland Consultants Inc. boosted its holdings in shares of Gilead Sciences by 0.4% in the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after buying an additional 39 shares in the last quarter. Arrow Financial Corp boosted its holdings in shares of Gilead Sciences by 0.3% in the 2nd quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock valued at $1,258,000 after buying an additional 45 shares in the last quarter. Finally, Westover Capital Advisors LLC boosted its holdings in shares of Gilead Sciences by 0.8% in the 1st quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock valued at $378,000 after buying an additional 46 shares in the last quarter. 74.62% of the stock is currently owned by institutional investors.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP James R. Meyers sold 60,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $83.19, for a total transaction of $4,991,400.00. Following the transaction, the executive vice president now owns 62,715 shares of the company’s stock, valued at $5,217,260.85. The disclosure for this sale can be found here. Insiders have sold a total of 666,819 shares of company stock valued at $52,303,086 over the last 90 days. 1.30% of the stock is currently owned by insiders.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.44 on Friday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The stock has a market cap of $94,626.13, a PE ratio of 7.56, a PEG ratio of -1.21 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s revenue was down 13.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.75 EPS. analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.69%.
Several research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Vetr cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 target price for the company. in a report on Monday, September 4th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $83.00 target price (up previously from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $84.87.
TRADEMARK VIOLATION WARNING: This report was reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/11/19/gilead-sciences-inc-gild-holdings-lowered-by-fiera-capital-corp.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.